Proove Biosciences’ Research Will Be Recognized and Presented at the American Academy of Neurology’s 66th Annual Meeting

Proove Biosciences’ P.A.I.N. Study Identifies Key Genes That Provide Insight As to Why Pain Tolerance is Different Among Individuals

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Statistical data supports Proove’s findings that a proprietary genotypic analysis from Proove can stratify pain perception, and may be a more objective method to define subjective numerical rating scales based on patient perceptions

Irvine, CA (PRWEB) April 29, 2014

Proove Biosciences, the leader in Personalized Pain Medicine testing services, will be presenting research identifying key genes that help understand why patients experience different levels of pain. Proove’s P.A.I.N. study evaluates whether genotype, or SNP variations can help identify how a individual patients will perceive pain, and is the background for the company’s new Proove Pain Perception Test. The study will be presented on Wednesday April 30th.

Proove’s PAIN Study abstract has received specific attention from the American Academy of Neurology because of the cutting edge nature of the researcher’s findings. A group of 2,721 people across 48 clinical sites diagnosed with chronic pain were tested for certain genes, and completed a Pain Numerical Rating Scale of their perception of pain on a scale from 1 to 10. Subjects with a rating of 0 were excluded. The study tested for the genes COMT, DRD2, DRD1, and OPRK1.

The research found that the DRD1 Variant was 33 percent more prevalent in the low pain group than in the high. Among people with moderate pain perception, the COMT and OPRK variants were 25 percent and 19 percent more often found than in those with a high pain perception. The DRD2 variant was found to be more common among the group with a high pain perception.

Statistical data supports Proove’s findings that a proprietary genotypic analysis from Proove can stratify pain perception, and may be a more objective method to define subjective numerical rating scales based on patient perceptions.

Proove Biosciences is the only company presenting research and hard data on how genetic tests can improve the efficiency of pain medication and treatment. Our research has been published, and is recognized in the field of pain medicine, and our P.A.I.N. Study in particular has garnered attention because of its ability to provide objective evidence and understanding to why pain is experienced differently among individual patients," stated Proove Biosciences CEO, Brian Meshkin. “As the only company able to present these statistically-driven findings, we are thrilled to share our research with the industry at the American Academy of Neurology’s 66th annual meeting.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).


Contact